Dr Reddys Laboratories Q2 Results Live : Dr Reddys Laboratories announced its Q2 results on November 5, 2024, revealing a mixed performance. In terms of market performance, Dr Reddys Laboratories has delivered a -0.2% return over the last week, a 1.65% return over the past six months, and a 9.71% return year-to-date. As of November 6, 2024, analysts remain cautious …
The Nifty closed at 21522.1, up by 0.95% on the trading day. When looking at the returns of the Nifty 50 over different time periods, it has shown the following performance: - In the last 1 week, it has given a return of 1.28%. The top gainers in the Nifty index were Dr Reddys Laboratories, Eicher Motors, Sun Pharmaceutical Industries, …
Mankind Pharma’s chairman has said the company’s will launch the cheapest Molnupiravir, the Covid-19 antiviral drug, at Rs 35 per capsule, the Economic Times said in a report. Molnupiravir, developed by MSD and Ridgeback Biotherapeutics, has been approved by the UK Medicines and Healthcare products Regulatory Agency and the US Food and Drug Administration for the treatment of mild-to-moderate Covid-19 …
The first batch of Russia’s Sputnik V vaccine for COVID-19 is likely to reach Kanpur’s Ganesh Shankar Vidyarthi Medical College by next week wherein the vaccine’s Phase 2 and Phase 3 human clinical trials will be conducted. The decision to conduct the human clinical trials of the vaccine was taken after Dr Reddy’s Laboratories got approval from the Drugs Controller …
